Regulatory Readiness for Medical Devices in Switzerland
Switzerland aligns its medical device regime with the EU MDR/IVDR but is a separate market: since the EU–CH Mutual Recognition Agreement (MRA) lapsed in May 2021, Switzerland treats EU as a third country and vice versa.
In Short
- Regulator: Swissmedic (Swiss Agency for Therapeutic Products) oversees medical devices in Switzerland.
- Switzerland mirrors EU MDR/IVDR classification.
- Switzerland does not operate a standalone premarket authorization for CE‑route devices.
Swissmedic enforces the Medical Devices Ordinance (MedDO) and In Vitro Diagnostic Medical Devices Ordinance (IvDO), which transpose MDR/IVDR largely verbatim while adding Swiss-specific obligations such as a Swiss Authorised Representative (CH-REP) and actor registration for a Swiss Single Registration Number (CHRN). Switzerland recognizes CE-marked devices under defined conditions and announced in 2024 a unilateral pathway to recognize certain FDA-approved devices to mitigate shortages. A Swiss EUDAMED-equivalent (swissdamed) is being built, and transitional provisions for legacy devices run, broadly, through 2028.
1) The regulator and the legal framework
Regulator: Swissmedic (Swiss Agency for Therapeutic Products) oversees medical devices in Switzerland. Statutes: the Therapeutic Products Act (TPA; SR 812.21) provides the legal basis; devices are governed by the Medical Devices Ordinance (MedDO; SR 812.213) and the In Vitro Diagnostic Medical Devices Ordinance (IvDO; SR 812.219).
More on 1) The regulator and the legal framework
These transpose EU Regulation (EU) 2017/745 (MDR) and 2017/746 (IVDR) into Swiss law, with Swiss-specific economic operator obligations. Major revisions: MedDO/IvDO were overhauled in 2020–2021 to align with MDR/IVDR, amended in 2023–2024 to extend transitional arrangements and to address the May 2021 lapse of the EU–CH MRA. Consequences of the MRA lapse: Swiss manufacturers are third-country manufacturers for the EU, requiring an EU Authorised Representative; non‑Swiss manufacturers require a Swiss Authorised Representative (CH‑REP) to place devices on the Swiss market. Switzerland continues to recognize EU CE certificates under conditions defined in MedDO/IvDO transitional provisions. In 2024, the Federal Council announced a unilateral recognition framework for certain FDA‑approved devices (scope defined by ordinance and Swissmedic guidance) without waiving Swiss PMS, vigilance, UDI, language, importer, or CH‑REP requirements. Actor registration (CHRN) is required; the national database swissdamed (Swiss EUDAMED equivalent) is under construction with phased go‑live.
2) Classification system in Switzerland
Switzerland mirrors EU MDR/IVDR classification. Medical devices: Class I (including subclasses Is, Im, Ir for sterile, measuring, reusable surgical), Class IIa, Class IIb, and Class III, per MDR Annex VIII rules (non‑invasive, invasive, active, special rules).
More on 2) Classification system in Switzerland
Active implantables are Class III. Software is classified per Rule 11. Accessories follow the rules applicable to their intended purpose. IVDs: Classes A, A sterile (As), B, C, and D under IVDR Annex VIII; most professional IVDs are B–D, while many lab instruments are A (often sterile As). Classification determines the conformity assessment route (self-declaration only for non‑sterile, non‑measuring Class I and Class A IVDs; all others require a Notified Body). Borderline/product status and classification follow Swissmedic guidance and MDCG documents adopted in Switzerland; when in doubt, seek a formal position from your Notified Body or Swissmedic. Misclassification is a primary cause of delays. Transitional provisions allow continued placement of qualifying legacy MDD/AIMDD devices (and IVDD) until dates in 2027/2028 (and later for IVDR) provided MDR/IVDR PMS, vigilance, and registration conditions are met.
3) Conformity assessment and market access
Switzerland does not operate a standalone premarket authorization for CE‑route devices. Manufacturers follow MDR/IVDR conformity assessment: self‑declaration for Class I (non‑sterile, non‑measuring) and IVDR Class A (non‑sterile); all other classes require a Notified Body certificate (EU NB).
More on 3) Conformity assessment and market access
Due to the MRA lapse, Swiss Conformity Assessment Bodies cannot issue CE certificates; use an EU‑designated NB. Switzerland recognizes valid CE certificates per MedDO/IvDO and applicable transitional measures. Economic operators must: appoint a Swiss Authorised Representative (CH‑REP) if the manufacturer is outside Switzerland (label and IFU must state the CH‑REP); designate a Swiss importer; register to obtain a Swiss Single Registration Number (CHRN). Technical documentation must meet MDR/IVDR Annex II/III (GSPRs, clinical/performance evaluation, PMS, UDI). For IVDs transitioning from IVDD, staged timelines apply, with NB involvement for most classes. In 2024, the Federal Council announced unilateral recognition of certain FDA approvals; scope is limited and does not exempt CH‑REP, language, UDI, PMS, or vigilance duties. swissdamed will become the platform for actor and, later, UDI/device registration; until modules are mandatory, follow Swissmedic registration instructions and maintain EUDAMED-equivalent data readiness.
4) QMS expectations and ISO 13485 mapping
More on 4) QMS expectations and ISO 13485 mapping
Switzerland accepts ISO 13485 certificates issued by accredited bodies; MDSAP certificates are not a legal substitute for MDR/IVDR QMS assessment but can streamline audits. Core elements include design and development controls, production and process controls, supplier controls, UDI/traceability, complaint and vigilance handling, PMS/PSUR, and CAPA. Risk management must follow ISO 14971 across lifecycle. Software lifecycle controls should map to IEC 62304 where applicable. Swiss economic operators (CH‑REP, importers, distributors) have defined QMS obligations (verification of CE mark/UDI/label language, storage, traceability, complaint forwarding). Maintain a Swiss-specific market file covering CH‑REP, importer, labeling languages, and Swissmedic reporting channels.
5) UDI, labeling, and language requirements
Switzerland has implemented an EU‑aligned UDI system via MedDO/IvDO. Devices must bear UDI‑DI and UDI‑PI on labels/packaging and, where required, direct part marking for reusable devices.
More on 5) UDI, labeling, and language requirements
UDI master data will be lodged in swissdamed once the UDI/device module is live; until then, maintain complete UDI datasets and ensure label/IFU carry UDI carriers and CE/NB details. Labeling must identify the CH‑REP for non‑Swiss manufacturers and the Swiss importer; symbols per ISO 15223‑1 are accepted. Language: safety information and IFU must be available in the national languages where the device is marketed (German, French, Italian). English may supplement but does not replace required local languages; professional‑use exceptions are narrow and must be justified. Electronic IFU is permitted for eligible device categories aligned with EU eIFU provisions, provided users can access required languages. Legacy devices under transition must progressively meet UDI and labeling updates as per Swiss transitional schedules, with full compliance at latest by 2028 for most legacy MDD devices.
6) Post-market surveillance, vigilance, and reporting
PMS must meet MDR/IVDR requirements as adopted in MedDO/IvDO. Maintain a PMS plan, collect and analyze complaints, trend data, and literature, and produce PMS Reports (Class I) or PSURs (Class IIa/IIb/III) at required intervals (IIa at least every two years; IIb/III annually).
More on 6) Post-market surveillance, vigilance, and reporting
PMCF/PMPF is expected where clinical/performance evidence needs reinforcement. Vigilance: serious incidents must be reported to Swissmedic using MIR-aligned formats and timelines equivalent to MDR Art. 87—serious public health threat within 2 days, death or unanticipated serious deterioration within 10 days, others within 15 days. Field Safety Corrective Actions require prompt notification and Field Safety Notices in applicable languages. Importers/distributors must forward complaints/adverse events and maintain traceability to UDI. Trend reporting applies per MDR Art. 88. Maintain periodic signal review and management review inputs. Swissmedic uses electronic submission channels; keep readiness for swissdamed vigilance modules as they phase in.
7) A 90–180 day readiness path for Switzerland
- Days 0–30
Assign RA lead for Switzerland; select and contract a CH‑REP and Swiss importer(s). Perform a MedDO/IvDO gap assessment against MDR/IVDR technical documentation and QMS. Confirm device classification and transitional eligibility (legacy vs new). Identify Notified Body status/certificate validity and renewal plan. Build a Swiss market file (CH‑REP/importer details, language plan, vigilance contacts).
- Days 31–60
Update labeling/IFU for CH‑REP/importer and DE/FR/IT; complete UDI master data; validate eIFU eligibility if applicable. Register actors with Swissmedic to obtain CHRN. Finalize PMS Plan/PSUR cadence and PMCF/PMPF needs. Configure vigilance channels and MIR templates.
- Days 61–90
Execute supplier qualification for CH‑REP/importers/distributors; train internal teams on Swiss obligations. Run an internal audit focused on MedDO/IvDO clauses, PMS, vigilance, and UDI. Prepare NB audit responses if certificates near expiry.
- Days 91–180
Close CAPA from the internal audit; perform labeling roll‑out and packaging changes; dry‑run a Swissmedic vigilance submission; ensure DHR capture for first Swiss lots. For software, confirm IEC 62304/CSV evidence alignment. Monitor Swissmedic updates on swissdamed and, if eligible, evaluate the 2024 FDA‑recognition pathway without compromising Swiss-specific PMS/label/UDI duties.
Questions
What timelines should we expect to enter the Swiss market?
If you already hold a valid CE certificate (or self-declaration for eligible Class I/A IVD), plan 90–180 days to contract a CH‑REP/importer, obtain CHRN, update labeling/IFU (DE/FR/IT), finalize UDI data, and align PMS/vigilance. Devices relying on Notified Body review (new or significant changes) depend on NB capacity (often 6–12 months). Legacy devices may use transitional provisions through 2027/2028 if conditions are met. swissdamed registration will add steps as modules become mandatory.
Do we need a Swiss Authorised Representative and what does it cost?
Yes. Any non‑Swiss manufacturer must appoint a CH‑REP; the CH‑REP’s name and address must appear on label/IFU and in registration. Costs vary by portfolio and risk class but commonly range from low five-figures CHF annually plus per-device fees and pass‑through for vigilance/FSCA support. Swiss importers also have obligations and may charge verification fees. Swiss manufacturers selling in the EU must additionally appoint an EU Authorised Representative due to the MRA lapse.
Is MDSAP accepted by Switzerland in lieu of MDR/IVDR assessments?
No. Switzerland aligns with MDR/IVDR; MDSAP is not a legal substitute for EU Notified Body conformity assessment or MDR/IVDR QMS evaluation. However, an MDSAP-certified QMS can reduce audit friction and evidentiary gaps, particularly for supplier controls, CAPA, complaint handling, and PMS. You still need applicable NB certificates (or self-declaration where allowed) and must meet Swiss-specific obligations such as CH‑REP, CHRN, labeling languages, UDI, and vigilance.
Does Switzerland recognize FDA 510(k), De Novo, or PMA approvals?
In 2024, the Federal Council announced a framework to unilaterally recognize certain FDA‑approved devices to mitigate supply shortages. Scope and conditions are defined by ordinance and Swissmedic guidance and are not a blanket equivalence to CE marking. Even when used, manufacturers must still appoint a CH‑REP, ensure Swiss language labeling and UDI, register actors (CHRN), and comply with PMS/vigilance. For most devices, CE conformity per MDR/IVDR remains the primary route.
What are the most common Swiss market access rejection or delay reasons?
Frequent issues include misclassification, expired or incomplete NB certificates, gaps in clinical/performance evaluation, missing CH‑REP or importer details on label/IFU, inadequate DE/FR/IT translations, incomplete UDI datasets or labeling, weak PMS/PMCF plans, and failure to obtain CHRN. For IVDs, underestimating IVDR NB involvement is common. Addressing these proactively with robust technical documentation, language controls, and defined Swiss economic operators reduces delays.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Medical Device Production Guide
Built to revision. Inspected. On record.
- What the QMSR changed in February 2026
- Supplier to finished build
- Inspect, review, correct
- Labels, UDI and traceability
Plus Evidence map and four worksheets.
Get the medical device guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Medical Device Production Guide
Built to revision. Inspected. On record.
Keep reading
- Global medical device regulatory readiness (2026)
Australia Medical Device Regulatory Readiness Guide
Brazil medical device regulatory readiness guide (ANVISA)
Canada Medical Devices Regulations (SOR/98-282) Readiness
China Medical Device Regulatory Readiness Guide 2026
EU MDR medical device regulatory readiness (European Union)